OverviewSuggest Edit

Impel NeuroPharma is a pharmaceutical company that develops and commercializes therapies for patients suffering from central nervous system diseases. Its technology targets the vascular-rich upper nasal cavity and provides rapid absorption, consistent drug biodistribution. The company specializes in the treatment of such diseases as migraine, autism spectrum disorder, and Parkinson's disease.

TypePublic
Founded2008
HQSeattle, WA, US
Websiteimpelnp.com
Employee Ratings4.2

Latest Updates

Employees (est.) (May 2021)67(+10%)
Share Price (Jun 2021)$9.8(+9%)
Cybersecurity ratingAMore

Key People/Management at Impel NeuroPharma

John Hoekman

John Hoekman

Co-Founder and CSO
Adrian Adams

Adrian Adams

Chairman & CEO
John Leaman

John Leaman

Chief Financial Officer
Stephen Shrewsbury

Stephen Shrewsbury

Chief Medical Officer
Leonard S. Paolillo

Leonard S. Paolillo

Chief Commercial Officer
Lynn Gold

Lynn Gold

Senior VP of Regulatory
Show more

Impel NeuroPharma Office Locations

Impel NeuroPharma has an office in Seattle
Seattle, WA, US (HQ)
Waterfront Research Center, 201 Elliott Ave W #260
Show all (1)

Impel NeuroPharma Financials and Metrics

Impel NeuroPharma Revenue

Market capitalization (4-Jun-2021)

190.8m

Closing stock price (4-Jun-2021)

9.8
Impel NeuroPharma's current market capitalization is $190.8 m.
Show all financial metrics

Impel NeuroPharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Impel NeuroPharma Online and Social Media Presence

Embed Graph

Impel NeuroPharma News and Updates

Impel NeuroPharma Announces First Quarter 2021 Financial Results and Provides Business Update

– Completed successful IPO raising approximately $80.0 million in gross proceeds –– NDA for TRUDHESA for treatment of acute migraine accepted for review by FDA; PDUFA date of September 6, 2021 –– Strengthened commercial capabilities with expanded management team and strategic collaboration with Veev…

Impel Neuropharma to Present Pivotal, Phase 3 Data From STOP-301 Study at The 63rd Annual Meeting of the American Headache Society

Data Will Evaluate Exploratory Efficacy Data from STOP-301 Study Evaluating INP104 Consistency of Response, Recurrence and Sustained Response

Impel NeuroPharma Launches Reroute Migraine Relief, Educational Initiative That Brings to Life the Underrecognized Connection Between Migraine, the Brain and Gut

Initiative Features Artwork from Internationally Renowned Artist Ed Fairburn, Specially Developed to Illustrate the Complexities of Migraine Initiative Features Artwork from Internationally Renowned Artist Ed Fairburn, Specially Developed to Illustrate the Complexities of Migraine

Impel NeuroPharma Presents Data From INP104 Clinical Program In Acute Migraine At The 2020 American Headache Society (AHS) Virtual Annual Scientific Meeting

SEATTLE, June 15, 2020 /PRNewswire/ -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced that...

Impel NeuroPharma to Present Data From INP104 Clinical Program at the 61st Annual Scientific Meeting of the American Headache Society

SEATTLE, July 10, 2019 /PRNewswire/ -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announcedthat...

Impel Neuropharma to Present Data at 2019 American Psychiatric Association (APA) Annual Meeting

SEATTLE, May 17, 2019 /PRNewswire/ -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies that unlock the full potential of proven medicines for patients living with central nervous system (CNS) disorders...
Show more

Impel NeuroPharma Blogs

Recurrence Rates for INP104 for the Acute Treatment of Migraine: Results from the Phase 3 STOP 301 Open-Label Study

Poster presented at the 2021 American Headache Society (AHS) Virtual Annual Scientific Meeting. Authors: Stewart J. Tepper, MD, Jessica Ailani, MD, Sheena K. Aurora, MD, Stephen B. Shrewsbury, MB ChB Introduction: Recurrence of migraine headache is common with acute treatment (particularly with the …

Treatment Consistency Across Multiple Migraine Attacks: Results From the Phase 3 Open-Label STOP 301 Study

Poster presented at the 2021 American Headache Society (AHS) Virtual Annual Scientific Meeting. Authors: Richard B. Lipton, MD, Barbara L. Nye, MD, Joe Hirman, PhD, Sheena K. Aurora, MD, and Stephen B. Shrewsbury, MB ChB Introduction: Since people with migraine treat multiple attacks with acute medi…

Acute Treatment of Migraine with INP104: Exploratory Efficacy from the Phase 3 Open-Label STOP 301 Study

Poster presented at the 2021 American Headache Society (AHS) Virtual Annual Scientific Meeting. Authors: Tim R. Smith, MD, Sheena K. Aurora, MD, Jasna Hocevar-Trnka, MD, Stephen B. Shrewsbury, MB ChB Introduction: Intravenous dihydroergotamine mesylate (DHE), although long used effectively to treat …

Nasal Safety of Chronic Intermittent Use of INP104: Results From the Phase 3 Open-Label STOP 301 Study

Poster presented at the 2021 American Headache Society (AHS) Virtual Annual Scientific Meeting. Authors: Greg Davis, MD, MPH, Adil Fatakia, MD, Seth Pransky, MD, Alison E. Heald, MD, Sheena K. Aurora, MD, Jasna Hocevar-Trnka, MD, Stephen B. Shrewsbury, MB ChB Objective: To assess the safety and tole…

Reduced Nausea When Dihydroergotamine Mesylate Is Delivered by INP104

Poster presented at the 2021 American Headache Society (AHS) Virtual Annual Scientific Meeting. Authors: LaDonna Randle, Sheena K. Aurora, MD, Jasna Hocevar-Trnka, MD, Stephen B. Shrewsbury, MB ChB Introduction: Dihydroergotamine mesylate (DHE) is an effective acute treatment for episodic migraine; …

DHE Pharmacology revisited: Does a broad receptor profile molecule treat the whole migraine?

Poster presented at the 2021 American Headache Society (AHS) Virtual Annual Scientific Meeting. Authors: Sheena K Aurora, Sutapa Ray, Kelsey Satterly, Lisa McConnachie, Stephen Shrewsbury, John Hoekman Introduction: Despite a growing body of science purporting migraine is a complex multifactorial br…
Show more

Impel NeuroPharma Frequently Asked Questions

  • When was Impel NeuroPharma founded?

    Impel NeuroPharma was founded in 2008.

  • Who are Impel NeuroPharma key executives?

    Impel NeuroPharma's key executives are John Hoekman, Adrian Adams and John Leaman.

  • How many employees does Impel NeuroPharma have?

    Impel NeuroPharma has 67 employees.

  • Who are Impel NeuroPharma competitors?

    Competitors of Impel NeuroPharma include Aerin Medical, Biocon Biologics and ReBio Technologies.

  • Where is Impel NeuroPharma headquarters?

    Impel NeuroPharma headquarters is located at Waterfront Research Center, 201 Elliott Ave W #260, Seattle.

  • Where are Impel NeuroPharma offices?

    Impel NeuroPharma has an office in Seattle.

  • How many offices does Impel NeuroPharma have?

    Impel NeuroPharma has 1 office.